INTRODUCTION {#S1}
============

Over the past 50 years, there have been dramatic improvements in the outcome of children with acute lymphoblastic leukemia (ALL): 5 year overall survival is now approaching 90%([@R1]-[@R3]). During this period, the Pediatric Oncology Group (POG) focused on risk- adapted therapy attempting to both limit toxicities and to maximize cures. Early studies for patients with lower risk B-precursor ALL focused on antimetabolite- based therapy, avoiding the use of anthracyclines, alkylating agents, and epipodophyllotoxins. Because patients with higher risk B-precursor ALL had an inferior outcome with antimetabolite- based therapy alone, further studies investigated the Goldie-Coldman hypothesis by the alternating use of anti-tumor agents that are relatively non-cross resistant to prevent the emergence of (or to treat) drug resistant leukemic clones.

Leukemic cells from children with T- cell ALL and Infant ALL have different biologic characteristics compared to those of children with B-precursor ALL. Therefore, these patients were treated on lineage and age specific protocols. Children with T- cell ALL were initially treated with rotating chemotherapeutic agents, including anthracyclines, alkylators, and epipodophyllotoxins along with intensification of asparaginase. However, because of a high rate of secondary malignancies, subsequent studies focused on intensification with asparaginase and methotrexate. Infants proved difficult to treat throughout this period with high rates of relapse, despite the use of antimetabolites, anthracyclines, alkylators, and epipodophyllotoxins.

From 1984-2001 the POG conducted seven studies for the treatment of B- precursor ALL, two for T- cell ALL and three for Infant ALL. In this paper we report the long term outcomes of patients enrolled on these studies.

MATERIALS AND METHODS {#S2}
=====================

Patients {#S3}
--------

Between 1984 and 2001, 7393 patients diagnosed with ALL were enrolled on twelve POG studies. Patients with B-precursor ALL (n=6524) were ≥ 12 months to ≤21.999 years of age. Patients with L3 morphology were treated on other studies. Patients with T -cell ALL (n=705) were also ≥ 12 months to ≤21.999 years of age. Infants with ALL (n=164; POG 8398/8493/9107) were \< 12 months of age. The POG 8398 and 8493 infant ALL protocols included infants with B-precursor (non- L3 morphology) and the occasional infant with T- cell ALL. Infants with T- cell ALL were not eligible for POG 9107. For all studies, patients could not have received prior therapy except for emergent treatment with steroids and/or radiation for severe respiratory distress. Blasts were Sudan black and/or myeloperoxidase negative and non-specific esterase negative. Immunophenotyping, chromosome analysis, and DNA index determination were performed at POG reference laboratories for all patients. On ALinC 16, patients also had reference laboratory flouresence in situ hybridization testing for trisomies 4 and 10 and subsets of patients had molecular screening for TEL-AML1 (ETV6-RUNX1) and/or for MLL rearrangements. Infants on the 8398, 8493, and 9107 protocols had subsequent MLL testing from cryopreserved bone marrow samples. All studies were approved by the institutional review board for each participating center. Informed consent was obtained prior to registration and treatment.

Treatments {#S4}
----------

### B-Precursor ALL {#S5}

Treatments are summarized in [Table 1](#T1){ref-type="table"}, and included 3 eras, Acute Leukemia in Children (ALinC) 14 - 16. Each POG study was numbered so that the first two numbers indicated the anticipated start year and the second two numbers indicated the study number within the category. POG 8602 (ALinC 14) included patients with both lower and higher risk disease. Subsequently, patients with lower or higher risk disease were treated on separate POG studies. Four POG studies focused on patients with lower risk disease (POG 9005, 9201, 9405, and 9605) and two POG studies focused on patients with higher risk disease (POG 9006 and 9406).

#### ALinC 14 (1986-1991) {#S6}

POG 8602 evaluated four different schedules of antimetabolite- based therapy ([@R4]-[@R6]). Patients with lower risk disease had: age 1 - \< 3 or 6 - \< 11 years and white blood cell (WBC) \< 10 × 10^3^/μL, or age 3 - \< 6 years and a WBC \< 100 × 10^3^/μL. Patients with higher risk disease had: age 1 - \< 3 or 6 - \< 11 years and WBC ≥ 10 × 10^3^/μL, age 3 - \< 6 years and WBC ≥ 100 × 10^3^/μL, or age ≥ 11 years. Patients with central nervous system disease (CNS3) at diagnosis (blasts on cytospin of the cerebrospinal fluid with WBC ≥ 5 cells/μL), or liver and/or spleen extending below the umbilicus, or with pre-B ALL (cytoplasmic immunoglobulin positive) or with Philadelphia chromosome \[t(9;22)\] positive blasts were considered higher risk disease, regardless of age and WBC. Patients with lower risk disease were randomized to one of the four post-induction regimens: (A) intermediate dose methotrexate (IDMTX) 1 g/m^2^, every 3 weeks × 6; (B) IDMTX every 3 weeks × 6 and L-asparaginase (Asp; Merck) 25,000 IU/ m^2^ intramuscular (IM) weekly × 24; (C) IDMTX and cytosine arabinoside (AC) 1 g/m^2^, every 3 weeks × 6; or (D) IDMTX/AC every 12 weeks × 6. Patients with higher risk disease by age and WBC or by liver/spleen measurement were randomized to regimens B, C, or D. Patients with pre-B ALL were randomized to regimen B or C. Patients who had t(9;22) or CNS3 were non-randomly assigned to regimen C. All patients received CNS prophylaxis with triple intrathecal therapy (TIT) including methotrexate, cytosine arabinoside, and hydrocortisone. Patients with CNS3 at diagnosis received craniospinal irradiation.

#### AlinC 15 (1991-1994) {#S7}

ALinC 15 evaluated three schedules of increased intensity methotrexate/mercaptopurine therapy for patients with lower risk disease (POG 9005)([@R7]). Patients with higher risk disease received increased intensity methotrexate/mercaptopurine with or without the addition of epipodophyllotoxins, anthracyclines, and cytosine arabinoside (POG 9006)([@R8]). Patients were risk classified based on age and WBC in the same manner as the POG 8602. Patients with CNS3, t(9;22), t(1:19) or testicular disease were classified as higher risk disease, regardless of age and WBC. Patients with higher risk disease based on age and WBC, no CNS3 disease, and a DNA index (flow cytometric measurement of the DNA of the leukemic blast compared to a normal cell) of \> 1.16 were risk adjusted into the lower risk group and treated on the POG 9005. Patients enrolled on the POG 9005 were randomized into three regimens: (A) IDMTX (1g/m^2^) and intravenous intermediate dose mercaptopurine (IDMP) 1 g/m^2^ every 2 weeks × 12; (B) oral MTX (30 mg/m^2^ every 6 hours × 6) and IDMP every 2 weeks × 12; or (C) IDMTX every 2 weeks × 12. Patients enrolled on POG 9006 were randomized into two regimens: (A) IDMTX/IDMP every 2 weeks × 12 or (B) rotating cycles of IDMTX/IDMP, teniposide (VM26)/AC and prednisone/vincristine/daunomycin/Asp/AC (PVDAsp/AC). Patients with t(9;22), t(1;19), or testicular disease were non-randomly assigned to regimen A. Patients with t(9;22) could proceed to transplant at investigator's choice. POG 9006 was later amended to pilot regimen C, which was identical to regimen B except that the IDMTX was 2.5 g/m^2^. All patients received CNS prophylaxis with TIT and patients with CNS3 at diagnosis received craniospinal irradiation.

#### ALinC 16 (1994-1999) {#S8}

ALinC 16 risk stratified patients into lower risk (POG 9201)([@R9]), standard risk (POG 9405 and 9605)([@R10]-[@R12]), and higher risk disease (POG 9406). This series first stratified based on age and WBC by National Cancer Institute (NCI) risk grouping: (1) standard risk - age 1 - 9 and WBC \< 50 × 10^3^/μL, or (2) high risk -- age ≥ 10 years or WBC ≥ 50 × 10^3^/μL ([@R13]). Patients with NCI standard risk and either (1) uninformative cytogenetics and DNA index \> 1.16, or (2) trisomies 4 and 10 were classified as having lower risk disease. Patients with NCI standard risk and (1) uninformative cytogenetics and DNA index ≤ 1.16 (or technically unsatisfactory DNA index), or (2) an abnormal karyotype but lacking trisomies 4 and 10; or NCI high risk and (1) uninformative cytogenetics and DNA index \> 1.16, or (2) trisomies 4 and 10 were placed in the standard risk group. Patients with NCI high risk and (1) uninformative cytogenetics and DNA index ≤ 1.16 (or technically unsatisfactory DNA index) or (2) an abnormal karyotype but lacking trisomies 4 and 10; or patients with CNS3, t(1;19), t(4;11), or t(9;22) regardless of NCI risk group were placed in the higher risk group. POG 9201, designed to confirm previous outcomes, was a single regimen study utilizing IDMTX for patients with lower risk disease. POG 9405 randomized standard risk patients to two doses of IDMTX (1 versus 2.5 g/m^2^) during intensification and to daily versus twice daily MP during continuation. POG 9405 was closed early due to neurotoxicity and replaced by POG 9605; only results from POG 9605 are reported with the ALinC 16 data. POG 9605 randomized patients in a 2×2 factorial design to IM MTX (regimens A/C) versus divided dose (dd) MTX (regimens B/D) ([@R14], [@R15]) and daily (regimens A/B) versus twice daily (regimens C/D) MP. POG 9406 evaluated rotating cycles of relatively non-cross resistant agents and randomized in a 2×2 factorial design to IDMTX, 1 g/m^2^ (regimens A/B) versus 2.5 g/m^2^ (regimens C/D) and to VM26/AC (regimens A/C) versus high dose AC (3 g/m^2^ every 12 hours × 4) (HDAC, regimens B/D). All ALinC 16 patients initially received CNS prophylaxis with TIT. Sixteen percent of patients enrolled on 9406/9605 developed grade 3-4 neurotoxicity (60% consisting of seizures). Subsequently, all patients were switched to intrathecal (IT) MTX alone on 9201/9406/9605. Patients with CNS3 at diagnosis received craniospinal irradiation.

### T- cell ALL {#S9}

POG 8704([@R16]) (1987-1992) randomized patients to +/− Asp (Merck) 25,000 IU/ m^2^ IM weekly × 20, beginning on day 99 of therapy. The backbone of therapy consisted of rotating combinations including antimetabolites, alkylating agents, anthracyclines, and epipodophyllotoxins. All patients received TIT for CNS prophylaxis. Patients with initial WBC \> 50 × 10^3^/μL received cranial irradiation and patients with CNS3 at diagnosis received craniospinal irradiation.

POG 9404([@R17]) (1996-2001) randomized patients in a 2×2 factorial design to +/− high dose MTX (5 g/m^2^) × 4 doses and to +/− dexrazoxane prior to doxorubicin infusions ([@R18]-[@R21]). The backbone consisted of V/doxorubicin(Dox)/P/MP every 3 weeks and Asp weekly × 20. All patients received CNS prophylaxis with IT MTX/AC and cranial irradiation. Patients with CNS2 (blasts on cytospin but WBC \< 5 cells/μL) or CNS3 at diagnosis received two additional doses of IT therapy.

### Infant ALL {#S10}

All three infant studies (POG 8398, 8493, and 9107) evaluated post-induction rotating cycles of combination chemotherapy. The POG 9407, which opened in 1996, continued as the Children's Oncology Group Study P9407 in 2001, and is not reported here. POG 8398 cycles included intravenous IVMTX/IVMP, VM26/AC, and D/AC([@R22], [@R23]). All infants received CNS prophylaxis with TIT; infants with CNS3 received additional doses of IT therapy during induction. POG 8493 cycles included VP16/AC, VP/Cy/AC, and MTX/MP([@R22], [@R23]). All infants received CNS prophylaxis with TIT; infants with CNS3 received 4 additional doses of IT therapy during induction. POG 9107 cycles included HDAC/D, VP16/AC, IVMTX/IVMP, and VP/Cy/AC. All infants received CNS prophylaxis with TIT; no additional therapy was given to patients with CNS3 disease.

STATISTICAL CONSIDERATIONS {#S11}
==========================

Event-free survival time was defined as the time from diagnosis to first event (induction failure, relapse, death, or second malignant neoplasm) or last contact for those who did not have an event. Overall survival time was defined as time from diagnosis to death or last contact. Event-free survival (EFS) and overall survival (OS) rates were computed by the method of Kaplan-Meier and were compared using the log-rank test([@R24]). Cox proportional hazards regression was used to identify independent prognostic factors for EFS. For patients who achieved complete remission (CR), cumulative incidence rates of isolated CNS or any (isolated plus combined) CNS relapse, therapy-related second malignancies, and remission deaths, were computed and compared using Gray's method adjusting for competing events([@R25]). Data sets were frozen as of 1/21/2009 for the analyses.

RESULTS {#S12}
=======

The 10 year EFS rate improved significantly across eras for patients with B-precursor ALL enrolled on ALinC14 (1986-1991), ALinC15 (1991-1994), and ALinC16 (1992-1999): 66.7 ± 1.2%, 68.1 ± 1.4%, and 73.2 ± 2.1%, respectively (p \< 0.0001; [Fig 1A](#F1){ref-type="fig"}). The 10 year OS rates for the three eras were 78.8 ± 1.0%, 82.8 ± 1.1%, and 85.3 ± 1.7%, respectively (p \< 0.0001; [Fig 1B](#F1){ref-type="fig"}). Similar improvements were seen for patients with T-cell ALL on POG 8704 (1987-1992) and POG 9404 (1996-2001): 10 year EFS 49.1 ± 3.1% versus 72.2 ± 4.7%, respectively (p \< 0.0001; [Fig 2A](#F2){ref-type="fig"}); 10 year OS 55.3 ± 3.1% versus 78.8 ± 4.4%, respectively (p \< 0.0001; [Fig 2B](#F2){ref-type="fig"}). EFS rates at 10 years for infants enrolled on POG 8398, 8493, and 9107, were of 17.7± 7.2%, 22.4 ± 5.5%, and 31.9 ± 8.3%, respectively. This difference did not however reach statistical significance. Detailed outcomes are given below.

Protocol Specific Treatment Outcome {#S13}
-----------------------------------

### B-Precursor ALL {#S14}

#### ALinC 14 {#S15}

For the 1933 evaluable patients enrolled on ALinC14 (1986-1991), POG 8602, the 10 year EFS and OS were 66.7 ± 1.2% and 78.8 ± 1.0%, respectively ([Fig 1A, 1B](#F1){ref-type="fig"}). [Table 2A](#T2){ref-type="table"} gives EFS and OS for ALinc14. [Table 2B](#T3){ref-type="table"} summarizes the outcomes by randomized regimens on POG 8602. Patients with lower risk disease receiving IDMTX (regimen A) had an EFS of 76.3 ± 3.1% and did not have better outcomes with the addition of Asp or AC. Patients with higher risk disease had an EFS of 58% with both of the IDMTX/AC regimens. Patients with pre-B ALL treated with IDMTX/AC at 3 week intervals (regimen C) had an improved outcome compared to those treated with IDMTX/Asp (regimen B) EFS of 70.3 ± 2.9% versus 63.2 ± 3.6% respectively (p=0.0246). [Table 2C](#T4){ref-type="table"} gives a summary of response and first events overall and by NCI risk group. The NCI standard risk patients had a CR rate of 98.2%, while the higher risk patients had a CR rate of 93.4% on this series. Induction failure and induction death rates for the standard risk patients were 0.52% and 0.81%, respectively. Corresponding rates for the higher risk patients were 4.5% and 1.9%, respectively. [Table 2D](#T5){ref-type="table"} gives the cumulative incidence rates both overall and by study. The 10 year cumulative incidence rates for isolated CNS and any CNS relapses on ALinC 14 were 4.3 ± 0.5% and 7.7 ± 0.6%, respectively ([Fig 1C](#F1){ref-type="fig"}). Cumulative incidence of secondary malignancies at 10 years was 0.6 ± 0.2%, and the incidence rate for remission deaths was 1.9 ± 0.3%.

#### ALinC 15 {#S16}

EFS and OS at 10 years for the 1896 patients on ALinC15 (1991-1994), POG 9005/9006, were 68.1 ± 1.4% and 82.8 ± 1.1%, respectively ([Fig 1A, 1B](#F1){ref-type="fig"}). EFS and OS for ALinC15 are summarized in [Table 2A](#T2){ref-type="table"}. Outcomes by randomized regimens are given in [Table 2B](#T3){ref-type="table"}. Patients with lower risk disease (POG 9005) had a better outcome with IDMTX/IDMP (regimen A) versus lower dose oral MTX/IDMP (regimen B), with an EFS of 77.5 ± 2.7% versus 66.3 ± 3.1% (p=0.0014), respectively. However, the addition of IDMP to IDMTX (regimen A) did not improve outcomes over IDMTX alone (regimen C). Acute neurotoxicity occurred in 7.8% of patients enrolled on the 9005, with 82% of events consisting of seizures. Other events included paresthesias, paresis, ataxia, aphasia, dysarthria, debilitating headaches, severe arachnoiditis, and choreoathetosis([@R26]). The incidence of neurotoxicity was higher on regimens A and C (8.3% and 11.2%, respectively) than on regimen B (3.7%), p \< 0.001. Magnetic resonance imaging (MRI) or computed tomography (CT) evidence of leukoencephalopathy was more commonly present in symptomatic patients on regimens A and C (75% and 77%, respectively) than on regimen B (15.4%), p\< 0.001. Patients with higher risk disease (POG 9006) had an EFS of 57.1 ± 2.1% and a similar outcome whether they received IDMTX/IDMP or rotating agents. [Table 2C](#T4){ref-type="table"} gives a summary of response and first events overall and by NCI risk group for ALinC15. The NCI standard risk patients had a CR rate of 98.3%, while the higher risk patients had a CR rate of 94.9% on this series. Induction failure and induction death rates for the standard risk patients were 0.52% and 0.52%, respectively. Corresponding rates for the higher risk patients were 3.4% and 1.1%, respectively. The cumulative incidence rates on ALinC 15 for isolated CNS and any CNS relapses were 4.8 ± 0.5% and 8.3 ± 0.6%, respectively ([Fig 1D](#F1){ref-type="fig"}, [Table 2D](#T5){ref-type="table"}). Cumulative incidence of secondary malignancies at 10 years was 0.8 ± 0.2%, and the incidence rate for remission deaths was 1.4 ± 0.3%. Cumulative incidence rates for secondary malignancies at 10 years were 0.7 ± 0.2% and 1.2 ± 0.5% on POG 9005 and 9006, respectively. Remission death rates on the two studies were 0.8 ± 0.3% and 2.8 ± 0.7%, respectively.

#### ALinC 16 {#S17}

For the 2637 evaluable patients enrolled on ALinC16 (1992-1999), POG 9201/9406/9605, the EFS and OS at 10 years were 73.2 ± 2.1% and 85.3 ± 1.7%, respectively ([Fig 1A, 1B](#F1){ref-type="fig"}). [Table 2A](#T2){ref-type="table"} summarizes EFS and OS for ALinC16. Patients with lower risk disease and favorable prognostic indicators (DNA index \> 1.16 or trisomies 4 and 10) had an EFS of 85.7 ± 2.7% ([Table 2B](#T3){ref-type="table"}) with IDMTX based therapy alone (POG 9201). Patients with standard risk disease (NCI standard risk with DNA index ≤ 1.16 or lacking trisomies 4 and 10; or NCI higher risk with DNA index \> 1.16 or trisomies 4 and 10) had an EFS of 73.4 ± 1.8% (POG 9605). There was a significant interaction between the two randomizations on that study, resulting in insufficient power to determine the superior regimen. Patients with higher risk disease (POG 9406) had EFS of 63.5 ± 1.7% and did not have improved outcomes with the use of HDAC or higher dose MTX. [Table 2C](#T4){ref-type="table"} gives a summary of response and first events overall and by NCI risk for ALinC16. The NCI standard risk patients had a CR rate of 99.0%, while the higher risk patients had a CR rate of 97.2% on this series. Induction failure and induction death rates for the standard risk patients were 0.23% and 0.29%, respectively. Corresponding rates for the higher risk patients were 1.5% and 1.0%, respectively. Cumulative 10 year incidence rates on ALinC16 for isolated CNS and any CNS relapses were 3.2 ± 0.3% and 6.1 ± 0.5%, respectively ([Fig 1E](#F1){ref-type="fig"}, [Table 2D](#T5){ref-type="table"}). Overall incidence of secondary malignancies and remission deaths were 0.8 ± 0.2% and 2.0 ± 0.4%, respectively. Incidence of secondary malignancies at ten years was 0.3 ± 0.2%, 0.7 ± 0.3%, and 1.2 ± 0.4%, respectively on POG 9201, 9605 and 9406. Remission death rates were 0.3 ± 0.2%, 1.0 ± 0.4%, and 4.4 ± 0.9%, respectively on the three studies.

### T- cell ALL {#S18}

#### POG 8704 {#S19}

For 342 evaluable patients enrolled on POG 8704 (1987-1992), the 10 year EFS and OS were 49.1 ± 3.1% and 55.3 ± 3.1%, respectively ([Fig 2A, 2B](#F2){ref-type="fig"}, [Table 3A](#T6){ref-type="table"}). Patients had an improved outcome with the addition of weekly asparaginase, with 10 year EFS rates of 61.8 ± 4.3% versus 42.7 ± 4.6% (p=0.0012) ([Table 3B](#T7){ref-type="table"}). [Table 3C](#T8){ref-type="table"} gives a summary of response and first events for this study. The CR rate at the end of induction was 95.3%. Induction failure and induction death rates were 1.5% and 2.6%, respectively. Overall cumulative incidence rates at 10 years for isolated CNS and any CNS relapses were 3.4 ± 1.0% and 9.8 ± 1.7%, respectively ([Fig 2C](#F2){ref-type="fig"}, [Table 3D](#T9){ref-type="table"}). Overall rate for secondary malignancies at 10 years was 4.0 ± 1.1%. Secondary malignancy rates at 10 years were 6.3 ± 1.9% and 1.9 ± 1.1% for patients receiving or not receiving weekly asparaginase (p=0.11). There were a total of 14 secondary malignancies (10 acute myeloid leukemia (AML), 1 myelodysplastic syndrome (MDS), 1 Acute Lymphoid Leukemia, 1 angiocentric lymphoma, and 1 primitive neuroectodermal tumor). Overall 10 year remission death rate was 3.1 ± 1.0%.

#### POG 9404 {#S20}

For 363 evaluable patients enrolled on POG 9404 (1996-2001), the 10 year EFS and OS were 72.2 ± 4.7% and 78.8 ± 4.4%, respectively ([Fig 2A, 2B](#F2){ref-type="fig"}, [Table 3A](#T6){ref-type="table"}). Patients had an improved outcome with the addition of HDMTX with a 10 year EFS of 78.0 ± 6.0% versus 65.8 ± 7.3% (p=0.029; [Table 3B](#T7){ref-type="table"}). The addition of dexrazoxane had no impact on EFS. [Table 3C](#T8){ref-type="table"} gives a summary of response and first events for this study. The CR rate at the end of induction was 91.5%. Induction failure and induction death rates were 7.4% and 0.83%, respectively. The 10 year cumulative incidence rates for isolated CNS and any CNS relapses were 7.0 ± 1.4% and 9.4 ± 1.6%, respectively ([Fig 2D](#F2){ref-type="fig"}, [Table 3D](#T9){ref-type="table"}). Secondary malignancies developed in 2.8 ± 1.2%, and remission deaths occurred in 1.9 ± 0.8% of patients. There were a total of 8 secondary malignancies (3 AML, 1 MDS, 2 non-Hodgkin lymphoma, 1 right cranial tumor, and 1 medulloblastoma). The 10 year cumulative incidence of secondary malignancies were 1.3 ± 0.9% and 4.2 ± 2.2% on the No Dexrazoxane vs Dexrazoxane regimens (p=0.15). Secondary malignancy rates on the No HDMTX vs HDMTX regimens were 4.1 ± 2.3% and 2.3 ± 1.3% (p=0.81), respectively.

### Infant ALL {#S21}

For the 164 evaluable infants on POG 8398 (1984-1990), POG 8493 (1984-1990), and POG 9107 (1991-1993), the overall 10 year EFS and OS rates were 24.1 ± 4.0% and 33.7 ± 4.4%, respectively ([Fig 3A](#F3){ref-type="fig"}). The CR rates ([Table 4B](#T11){ref-type="table"}) at the end of induction on the three studies were 93.9%, 89.3%, and 89.4%, respectively. Induction failure and induction death rates on 8398 were 6.1% and 0%. Study 8493 had induction failure and induction death rates of 2.4% and 7.1%, respectively. On study 9107, these rates were 2.1% and 6.4%. The overall cumulative incidence rates for isolated CNS and any CNS relapses were 3.4 ± 1.5% and 14.3 ± 2.9%, respectively ([Fig 3B](#F3){ref-type="fig"}, [Table 4C](#T12){ref-type="table"}). Although outcomes improved progressively over the three studies (EFS 17.7 ± 7.2%, 22.4 ± 5.5%, 31.9 ± 8.3%; [Table 4A](#T10){ref-type="table"}) this did not reach statistical significance (p=0.66). There were no secondary malignancies seen on either POG 8398 or 8493. Secondary malignancies developed in 3.3 ± 3.4% of patients enrolled on POG 9107. Overall remission death rate at 10 years was 8.2 ± 2.3%.

Treatment Results According to Presenting Features {#S22}
--------------------------------------------------

Univariate and multivariate Cox regression analyses were conducted by presenting features for B-precursor, T-cell, and Infant ALL. Factors considered include, NCI risk, gender, age at diagnosis, race, WBC at diagnosis, CNS status, DNA index, presence of trisomies 4 and 10, TEL-AML1, t(9;22), t(1;19), and t(4;11) translocations. All data (except for TEL-AML1 status) were available for most of the patients. TEL-AML1 status was known only for 926 patients on the ALinC16 series of studies for B-precursor ALL.

### B-precursor ALL {#S23}

Univariate analyses are summarized in [Table 2A](#T2){ref-type="table"} for B-precursor ALL. Multivariate analyses ([Table 5](#T5){ref-type="table"}) included NCI risk, gender, age, race, WBC, CNS status, DI, presence of translocations t(9;22), t(1;19), t(4;11), and trisomies 4 and 10. A total of 4959 patients were included in the analysis. Since TELAML1 status was missing for most of the patients, it was excluded from the multivariate analyses. Males and patients \>10 years of age had worse outcomes (HR: 1.5 and 1.64, respectively). Hispanics and blacks had significantly lower EFS compared to whites (HR: 1.39 and 1.29, respectively). Patients with WBC \< 10 × 10^3^/μL have significantly better outcomes compared to those with higher values; those with WBC\>100 × 10^3^/μL had the worst outcomes. Having CNS disease, or the t(9;22) translocation was associated with poor outcomes (HR: 1.34 and 3.73, respectively). Patients with DI ≤ 1.16 had worse outcomes compared those with 1.16 \< DI \<1.60. Presence of trisomies 4 and 10 (HR:0.74) and t(1;19) (HR:0.71) were associated with good prognosis. Presence of t(4;11) did not reach statistical significance (HR: 1.37).

### T-cell ALL {#S24}

Univariate analyses are summarized in [Table 3A](#T6){ref-type="table"} for T-cell ALL. All 705 patients were part of the multivariate Cox regression analyses which included NCI risk, gender, age, race, WBC, and CNS status as prognostic factors ([Table 5](#T5){ref-type="table"}). Gender was a significant predictor of EFS (HR: 1.744, p=0.0005); males had worse outcomes. No other factors were predictive in the multivariate model.

### Infant ALL {#S25}

Univariate analyses are summarized in [Table 4A](#T10){ref-type="table"} for Infant ALL. Multivariate analyses included lineage (B-precursor vs T), gender, race, WBC, CNS status, and presence of t(4;11) translocation in the model ([Table 5](#T5){ref-type="table"}). A total of 148 patients had complete data and were included in the analysis. Patients with 50\<WBC\<100 × 10^3^/μL (HR: 2.132, p=0.0093) and WBC≥100 × 10^3^/μL (HR: 2.45, p=0.0003) had worse outcomes compared to WBC\<50 × 10^3^/μL. Presence of the t(4;11) translocation tended to predict poorer outcomes (HR: 1.53, p=0.056).

DISCUSSION {#S26}
==========

B- Precursor ALL {#S27}
----------------

### ALinC 14 {#S28}

All patients received antimetabolite based therapy which was less effective for patients with higher risk disease. No regimen was superior in either risk group, although it should be noted that patients with higher risk disease were not randomized into regimen A (IDMTX alone). In subgroup analysis, patients with pre-B ALL had an improved outcome with every 3 week IDMTX/AC versus every 3 week IDMTX and weekly asparaginase. Outcomes in the IDMTX/Asp group did not correlate with number of doses of asparaginase received.

### ALinC 15 {#S29}

POG 9005 intensified therapy by compression of MTX intensification cycles to every 2 weeks (from every 3 weeks on the 8602). In addition IDMP was added to the courses of either IDMTX or PO MTX during intensification. IDMTX/IDMP was superior to PO MTX/IDMP([@R7]). However, these results showed no improvement over those obtained on the POG 8602 with IDMTX every 3 weeks without IDMP. In addition, results with IDMTX alone (regimen C) were similar to results of IDMTX/IVMP (regimen A). These data indicated that IDMP did not add benefit to IDMTX. The incidence of acute neurotoxicity was increased on regimens A and C of this trial that included IDMTX every 2 weeks (8.3% and 11.2%, respectively) compared to PO MTX/IDMP, 3.7% (p \< 0.001). The addition of IDMP to IDMTX did not increase the incidence of acute neurotoxicity over IDMTX alone([@R26]). Neurotoxicity on the POG 9005 was higher than the 2.6% reported on the POG 8602 where IDMTX was administered every 3 weeks([@R5]). Further analyses of the neurotoxicity (mostly seizures) suggested that this was due to a combination of: a. an increased frequency and cumulative dose of IDMTX, b. an increased methotrexate:leucovorin ratio and c. the timing of leucovorin in relation to the intrathecal treatments . There was no evidence implicating an increased risk of neurotoxicity with the use of TIT.

Early results of POG 9006 suggested an improved outcome for higher risk patients treated with rotating cycles of agents, resulting in early trial closure. However, longer follow-up showed no differences in EFS, although toxicity was increased with the rotating cycles of agents ([@R8]). This may indicate that agents chosen to test the Goldie-Coldman hypothesis were either not equally effective or were cross resistant. Additionally, the more intensive every 2 week IDMTX/IDMP regimen, like on the POG 9005, provided no improvement in outcome compared to higher risk patients treated on POG 8602.

### ALinC 16 {#S30}

POG 9201, utilizing regimen A of POG 8602 confirmed our earlier favorable results for very low risk patients treated with IDMTX based therapy([@R9], [@R27]-[@R29]). The POG 9405 was closed early due to excessive grade 2-4 neurotoxicity (Common toxicity Criteria 2.0) (19% of patients, n=57). More than half of these events were seizures. Other events included cerebellar and motor deficits, cognitive dysfunction, headaches, and significant fatigue. Neither the efficacy nor toxicity of the two MTX schedules could be fully evaluated ([@R10]). POG 9605 replaced this study and returned to the intensification regimen A of POG 8602([@R14], [@R15]). Excessive neurotoxicity was again seen, and the study was amended to replace TIT with IT MTX. Further analysis of neurotoxicity, however, suggested the cause was more complex (see discussion of ALinC 15 above). There was no evidence implicating an increased risk of neurotoxicity with the use of TIT. Although there were no significant differences in outcomes within the MTX and MP study questions, when reviewed by regimen significant differences were evident, with the IM MTX/twice daily MP and dd MTX/daily MP arms demonstrating improved survivals. This suggested that the manner in which these antimetabolites were given influenced outcomes. However, because this trial was designed as a 2×2 factorial, it was not powered to compare the four arms([@R11], [@R12]).

Higher risk patients, POG 9406, received rotating cycles of non-cross resistant agents based on the early results of POG 9006. Patients were randomized between two doses of IDMTX based on results suggesting that higher steady state MTX levels would improve outcomes and HDAC/Asp versus VM26/AC in an attempt to improve outcomes without increasing the risk of secondary malignancies associated with epipodophyllotoxins. Neither of these strategies improved outcomes.

### ALinC 14-16 {#S31}

The incidence of isolated CNS relapse in patients enrolled on ALinC 14-16 was 3.2 to 4.8% at 10 years, with prophylactic age adjusted IT therapy for all patients and irradiation for patients with CNS3 disease at diagnosis. Despite more aggressive therapy, the incidence of isolated CNS relapse was increased in higher versus lower risk patients, 5.8 ± 0.5% versus 3.2 ± 0.3%, respectively, emphasizing the more resistant nature of the leukemic clone in higher risk patients and suggesting that either the chemotherapeutic agents or their dosing regimens did not provide adequate CNS penetration. A decrease in isolated CNS relapse rate was seen on the POG 9406 with the use of high dose antimetabolite therapy versus intermediate dose antimetabolite therapy utilized on the POG 9006. Other agents with increased CNS penetrance, such as dexamethasone, were not used in these studies, but may play an important role in higher risk disease. Secondary malignancies remained about 1% across all studies, despite the use of epipodophyllotoxins in higher risk patients. Despite increasing intensity across the ALinC 14-16, the percent of patients who failed initial therapy but achieved long term survival remained constant at approximately 50%. This is similar to findings of the Children's Cancer Group, where survival after relapse was not different between earlier and later trials conducted between 1988 and 2002([@R30]).

T-cell ALL {#S32}
----------

### POG 8704 {#S33}

The backbone of rotating agents for this protocol was chosen based on previous combinations that were shown to be effective against T- cell ALL and non-Hodgkin lymphoma([@R18], [@R31]-[@R33]). The addition of asparaginase improved outcome, consistent with outcomes seen on the Dana-Farber Cancer Institute (DFCI) series, where consolidation included both additional doxorubicin and asparaginase([@R34], [@R35]). Although the rate of secondary malignancies was increased in patients with T-cell ALL receiving asparaginase, this did not reach statistical significance. However, it should be noted that this was a subgroup analysis, and when all patients enrolled on the POG 8704, T-cell ALL and lymphoblastic lymphoma([@R16]), were included in the analysis the use of asparaginase was associated with a significantly increased rate of secondary malignancies. This is consistent with other studies where epipodophyllotoxins were combined with asparaginase([@R36]). Because epipodophyllotoxins are highly bound to plasma proteins, an asparaginase induced decrease in protein synthesis may result in an increase in the unbound epipodophyllotoxin fraction in the plasma and an increased risk of secondary malignancies([@R37]).

### POG 9404 {#S34}

The backbone of POG 9404 was based on the Dana-Farber Cancer Institute (DFCI) 87-01, which lacked epipodophyllotoxins but contained anthracyclines that resulted in late cardiac toxicity. The HDMTX regimens had improved outcomes, due to decreased induction failures and CNS relapse rates, and resulted in early closure of the No HDMTX regimens([@R17]). The addition of dexrazoxane did not have an adverse impact on the 10 year EFS. However, late effects of dexrazoxane on cardiac function are still to be determined. Secondary malignancies occurred in 2.8 ± 1.2% of patients, and were not associated with the use of HDMTX or dexrazoxane.

### POG 8704/9404 {#S35}

The incidence of isolated CNS relapse in patients enrolled on POG 8704 and on POG 9404 was 3.4% and 7.0%, respectively, at 10 years. All patients received prophylactic age adjusted IT therapy and all CNS3 and higher risk patients on 8704, as well as all patients enrolled on POG 9404, received CNS irradiation. Despite the universal application of CNS irradiation on POG 9404, CNS relapse rates did not decrease on this study. This may be a reflection of the limited use of prophylactic IT therapy on the POG 9404 versus 8704, where patients received fewer doses of IT, 10 versus 17, respectively. Overall secondary malignancies in T-cell ALL (2.8 to 4%) remained higher than that for patients with B-precursor ALL. Only 25% of relapsed T-ALL patients achieved long-term survival, significantly lower than similar patients with B-precursor disease.

Infant ALL {#S36}
----------

Throughout this period results were poor. Although there is a suggestion of improving outcomes, this did not reach statistical significance. The incidence of isolated CNS relapse in patients on POG 8398/8493/9107 was 3.4 ± 1.5% at 10 years, despite using no CNS irradiation due to the certainly of a poor neurocognitive outcome. There was one secondary malignancy at year 12 among the 148 patients in remission on these studies.

Prognostic Indicators {#S37}
---------------------

Prognostic indicators identified on the POG studies are similar to those found by other investigators. Significantly, however, gender remained a prognostic indicator on both the B-precursor and T-cell ALL studies. On each of the POG studies, male and female patients were treated with the same duration of therapy. Gender has also been shown to be a prognostic indicator by others, who have chosen to treat males for a year longer than females([@R38]-[@R41]). However, it is unclear whether longer duration of therapy or early intensification of therapy actually improves outcomes for males.

CONCLUSION {#S38}
==========

Over this series of studies we investigated the use of antimetabolite based and rotating agent therapy for the treatment of ALL. The use of IDMTX (1 g/m^2^) every three weeks improved outcomes for patients with B-precursor ALL. However, with the exception of HDMTX for the treatment of T-cell ALL, further intensification strategies were unsuccessful, suggesting that we have maximized our ability to eradicate drug resistant clones with antimetabolite based therapy. Additionally, the use of rotating agents had limited impact on higher risk disease. Although this may indicate that the Goldie-Coldman hypothesis is incorrect, it is also possible that the choice or schedule of the agents was not optimal, as other studies utilizing rotating agents have improved outcomes([@R39], [@R42], [@R43]). The POG series has demonstrated that patients with lower risk B-precursor ALL can be successfully treated with antimetabolite based therapy, and future studies will need to balance further improvements in outcome against the toxicities associated with therapy. Patients with higher risk B-precursor ALL require therapy directed at early identification([@R44]-[@R48]) and treatment of the resistant clone, and may include agents not explored on this series, such as dexamethasone or alkylators. A key strategy to improving the outcome of very high risk patients will be to identify recurrent genetic lesions present in patient subgroups and develop molecularly targeted therapies directed at these lesions, as has been so effective in Ph+ ALL. Patients with T-cell ALL and infant ALL will require novel agents([@R49], [@R50]), as there is limited ability to further intensify therapy.
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T-Cell ALL (A) Event-Free Survival by Study, (B) Overall Survival by Study, (C) POG 8704: Cumulative Incidence Rates of all CNS relapse, isolated CNS relapse, SMN, and death, (D) POG 9404: Cumulative Incidence Rates of all CNS relapse, isolated CNS relapse, SMN, and death
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Infant ALL (A) EFS and Overall Survival, (B) Cumulative Incidence Rates of all CNS relapse, isolated CNS relapse, SMN, and death
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Pediatric Oncology Group Treatment Overview

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                        **B-Precursor**                                                      **T-cell**                            **Infant**                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  --------------------- -------------------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------ ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------- ------------------------------------------- --------------- --------------- ---------------
  **Induction**         PVAsp                                                                PVAsp                                 PVDAsp                                                               PVAsp                                                                   PVAsp                                PVDAsp                                                                                                PVAsp                                                                  PVDoxCy\                                  PVDox/MTX/MP\                               PVDAsp          VP/Cy/AC        VP/Cy/AC
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  AC/Cy/Asp                                 \                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [Randomize]{.ul}\                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (4 groups)\                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ± HDMTX × 4\                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ± Dexrazoxane                                                               

  **Intensification**   [Randomize]{.ul}\                                                    [Randomize]{.ul}\                     [Randomize]{.ul}\                                                    IDMTX\                                                                  [Randomize]{.ul}\                    [Randomize]{.ul}\                                                                                     IDMTX\                                                                 AC/VM26\                                  VPDox/MP/Asp\                               IVMTX/IVMP\     VM26/AC\        HDAC/D\
                        IDMTX\                                                               IDMTX/IDMP\                           IDMTX (1 g/m^2^)\                                                    q3wk × 6\                                                               IDMTX\                               IDMTX (1 g/m^2^)\                                                                                     q3wk × 6\                                                              PVDox\                                    (27 wk total)                               × 6\            (3 wk total)\   VP16/AC\
                        q3wk × 6\                                                            q2wk × 12                             + IDMP\                                                              VP                                                                      (1 g/m^2^)\                          + IDMP × 6\                                                                                           VP\                                                                    (8 wk total)                                                                          VM26/AC × 3\    then,           IVMTX/IVMP\
                        VP                                                                                                         q2wk × 12                                                                                                                                    + IDMP\                              VM26/AC × 3\                                                                                          (20 wk total),\                                                                                                                                              D/AC × 3\                       VP/Cy/AC\
                                                                                                                                                                                                                                                                                q4wk × 12                            PVDAsp/AC × 3\                                                                                        then\                                                                                                                                                        (30 wk total)                   (52 wk total)
                                                                                                                                                                                                                                                                                                                     (30 wk total)                                                                                         \                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                           [Randomize]{.ul}\                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                           IM MTX\                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                           qwk × 28\                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                           PO MP(qd)\                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                           VP                                                                                                                                                                                           

                        IDMTX\                                                               PO MTX/IDMP\                          IDMTX (1 g/m^2^)\                                                                                                                            IDMTX\                               IDMTX (1 g/m^2^)\                                                                                     ddMTX\                                                                                                                                                                       MTX/MP\         
                        q3wk × 6 +\                                                          q2wk × 12                             + IDMP × 6\                                                                                                                                  (2.5 g/m^2^)\                        + IDMP × 6\                                                                                           qowk × 14\                                                                                                                                                                   VP/Cy/AC\       
                        Asp qwk\                                                                                                   VM26/AC × 3\                                                                                                                                 + IDMP\                              HDAC/Asp × 3\                                                                                         PO MP(qd)\                                                                                                                                                                   VM26/AC\        
                        × 24\                                                                                                      PVDAsp/AC × 3\                                                                                                                               q4 wk X 12                           PVDAsp/AC × 3                                                                                         VP                                                                                                                                                                           (96 wk\         
                        VP                                                                                                         (30 wk total)                                                                                                                                                                                                                                                                                                                                                                                                                                                        total)          

                        IDMTX/AC\                                                            IDMTX\                                [Pilot]{.ul}\                                                                                                                                                                     IDMTX (2.5 g/m^2^)\                                                                                   IM MTX\                                                                                                                                                                                      
                        q3wk × 6\                                                            q2wk × 12                             IDMTX (2.5 g/m^2^)\                                                                                                                                                               + IDMP × 6\                                                                                           qwk × 28\                                                                                                                                                                                    
                        VP                                                                                                         + IDMP × 6\                                                                                                                                                                       VM26/AC × 3\                                                                                          PO MP(BID)\                                                                                                                                                                                  
                                                                                                                                   VM26/AC × 3\                                                                                                                                                                      PVDAsp/AC × 3                                                                                         VP                                                                                                                                                                                           
                                                                                                                                   PVDAsp/AC × 3\                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                   (30 wk total)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                        IDMTX/AC\                                                                                                                                                                                                                                                                                    IDMTX (2.5 g/m^2^)\                                                                                   ddMTX\                                                                                                                                                                                       
                        q12wk × 6\                                                                                                                                                                                                                                                                                   + IDMP × 6\                                                                                           qowk × 14\                                                                                                                                                                                   
                        VP                                                                                                                                                                                                                                                                                           HDAC/Asp × 3\                                                                                         PO MP(BID)\                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                     PVDAsp/AC × 3                                                                                         VP                                                                                                                                                                                           

  **Continuation**      MTX/MP\                                                              MTX/MP                                MTX/MP                                                               MTX/MP\                                                                 [Randomize]{.ul}\                    MTX/MP                                                                                                [Continue MP as]{.ul}\                                                 [Randomize]{.ul}\                         MTX/MP\                                     MTX/MP          MTX/MP\         MTX/MP\
                        VP q16 wk                                                                                                                                                                       VP q16 wk                                                               IM MTX\                                                                                                                                    [Randomized]{.ul}\                                                     AC/Cy\                                    VP q3 wk                                                    PV q12 wk       VP16/AC\
                                                                                                                                                                                                                                                                                PO MP(BID)                                                                                                                                 IM MTX\                                                                PVDox/MP\                                                                                                             VP/Cy/AC\
                                                                                                                                                                                                                                                                                                                                                                                                                           PO MP\                                                                 AC/VM26\                                                                                                              (50 wk total)
                                                                                                                                                                                                                                                                                                                                                                                                                           VP q16 wk × 4                                                          \                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ± Asp qwk\                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  × 20                                                                                                                  

                                                                                                                                                                                                                                                                                IM MTX\                                                                                                                                    IM MTXPO MP(qd)\                                                                                                                                                                             
                                                                                                                                                                                                                                                                                PO MP(qd)                                                                                                                                  VP q16 wk × 4                                                                                                                                                                                

  **CNS**\              TIT [a](#TFN4){ref-type="table-fn"}[b](#TFN5){ref-type="table-fn"}   TIT [a](#TFN4){ref-type="table-fn"}   TIT [a](#TFN4){ref-type="table-fn"}[b](#TFN5){ref-type="table-fn"}   IT MTX [a](#TFN4){ref-type="table-fn"}[c](#TFN6){ref-type="table-fn"}   TIT[a](#TFN4){ref-type="table-fn"}   IT MTX[a](#TFN4){ref-type="table-fn"}[b](#TFN5){ref-type="table-fn"}[c](#TFN6){ref-type="table-fn"}   IT MTX[a](#TFN4){ref-type="table-fn"}[c](#TFN6){ref-type="table-fn"}   TIT[a](#TFN4){ref-type="table-fn"}\       IT MTX/AC[a](#TFN4){ref-type="table-fn"}\   TIT             TIT             TIT
  **prophylaxis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 CXRT[d](#TFN7){ref-type="table-fn"} or\   CXRT                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  CSXRT [b](#TFN5){ref-type="table-fn"}                                                                                 

  **Duration of**\      156 wks from\                                                        130 wks of\                           130 wks of CCR                                                       130 wks\                                                                130 wks from\                        130 wks of CCR                                                                                        130 wks from\                                                          104 wks\                                  104 wks of\                                 130 wks of\     156 wks\        104 wks of\
  **Therapy**           diagnosis                                                            CCR                                                                                                        from\                                                                   diagnosis                                                                                                                                  diagnosis                                                              from\                                     CCR                                         CCR             from\           CCR
                                                                                                                                                                                                        diagnosis                                                                                                                                                                                                                                                                                 diagnosis                                                                                             diagnosis       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

P-prednisone, V-vincristine, Asp-aspariginase, D-daunomycin, Dox -- doxorubicin, Cy-cytoxan, AC-cytosine arabinoside, MTX -- methotrexate, MP-6 mercaptopurine, IDMTX-intermediate dose MTX (1 g/m^2^ except POG 9006/9405/9406),

IDMP-intermediate dose MP (1 g/m^2^), HDMTX -- High dose MTX (5 g/m^2^), VM26 -- teniposide, VP16 -- etoposide, ddMTX -- divided dose MTX, HDAC-high dose cytosine arabinoside

BID -- twice daily, TIT intrathecal MTX/AC/hydrocortisone, IT -- intrathecal, CCR- continuous complete remission

age adjusted,

craniospinal irradiation (CSXRT) for CNS3,

amended from TIT,

cranial irradiation (CXRT) for WBC\>50,000

###### 

B-precursor ALL: Outcomes by Presenting Features

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factors                No. of\                              Event-free survival ± SE (%)   Overall survival ± SE (%)                                                                      
                         patients\                                                                                                                                                          
                         [\*\*](#TFN8){ref-type="table-fn"}                                                                                                                                 
  ---------------------- ------------------------------------ ------------------------------ --------------------------- ------------- ----------- ------------ ------------- ------------- -----------
  **Era**                                                                                                                                                                                   

  ALinC14                1933                                 70.5 ± 1.1                     66.7 ± 1.2                  65.4 ± 1.7    \< 0.0001   82.3 ± 0.9   78.8 ± 1.0    77.1 ± 1.5    \< 0.0001

  ALinC15                1896                                 71.6 ± 1.1                     68.1 ± 1.4                                            86.3 ± 0.8   82.8 ± 1.1    80.5 ± 35.5   

  ALinC16                2637                                 76.9 ± 0.8                     73.2 ± 2.1                                            88.6 ± 0.6   85.3 ± 1.7                  

  **NCI Risk**                                                                                                                                                                              

  Standard               4468                                 79.2 ± 0.6                     75.9 ± 0.9                  74.1 ± 1.9    \< 0.0001   91.0 ± 0.4   88.3+ 0.7     86.8 ± 1.4    \< 0.0001

  High                   2052                                 61.3 ± 1.1                     56.6 ± 1.7                  55.3 ± 3.5                75.7 ± 1.0   70.3 ± 1.5    67.4 ± 3.2    

  **Gender**                                                                                                                                                                                

  Male                   3587                                 69.5 ± 0.8                     65.2 ± 1.2                  63.5 ± 2.4    \< 0.0001   84.7 ± 0.6   80.9 ± 0.9    79.0 ± 2.0    \< 0.0001

  Female                 2937                                 78.5 ± 0.8                     75.6 ± 1.2                  74.0 ± 2.3                87.9 ± 0.6   84.9 ± 0.9    83.1 ± 2.0    

  **Age at diagnosis**                                                                                                                                                                      

  1-9 yrs                5255                                 76.9 ± 0.6                     73.5 ± 0.9                  71.9 ± 1.8    \< 0.0001   89.3 ± 0.4   86.5 ± 0.7    85.1 ± 1.4    \< 0.0001

  ≥10 yrs                1269                                 59.8 ± 1.4                     54.7 ± 2.2                  52.8 ± 4.9                73.1 ± 1.3   66.3 ± 2.1    62.1 ± 4.5    

  **Race**                                                                                                                                                                                  

  White                  4691                                 75.3 ± 0.6                     71.6 ± 0.9                  69.7 ± 1.9    \< 0.0001   87.7 ± 0.5   84.3 ± 0.7    82.3 ± 1.5    \< 0.0001

  Black                  584                                  67.1 ± 2.0                     63.7 ± 3.0                  63.7 ± 6.9                77.1 ± 1.8   73.7 ± 2.7    72.7 ± 6.4    

  Hispanic               839                                  67.2 ± 1.7                     63.5 ± 2.9                  63.5 ± 7.2                82.2 ± 1.4   76.7 ± 2.5    75.7 ± 7.1    

  Other                  410                                  75.7 ± 2.2                     71.8 ± 3.3                  70.0 ± 5.9                89.4 ± 1.6   88.0 ± 2.4    87.1 ± 4.3    

  **WBC×10^3^/μl**                                                                                                                                                                          

  \<10                   3561                                 79.4 ± 0.7                     75.7 ± 1.0                  73.8 ± 2.1    \< 0.0001   90.2 ± 0.5   87.2 ± 0.8    85.3 ± 1.7    \< 0.0001

  10-50                  1947                                 70.7 ± 1.1                     67.2 ± 1.6                  65.5 ± 3.2                84.9 ± 0.8   80.6 ± 1.3    79.0 ± 2.8    

  50-100                 571                                  65.2 ± 2.0                     60.7 ± 3.0                  60.1 ± 5.5                80.7 ± 1.7   77.2 ± 2.5    75.2 ± 4.8    

  ≥100                   441                                  49.7 ± 2.4                     46.2 ± 3.7                  45.3 ± 9.0                66.4 ± 2.3   62.4 ± 3.3    60.0 ± 7.7    

  **CNS status**                                                                                                                                                                            

  CNS negative           6322                                 73.9 ± 0.6                     70.3 ± 0.8                  68.7 ± 1.7    \< 0.0001   86.5 ± 0.4   83.2 ± 0.7    81.4 ± 1.4    \< 0.0001

  CNS positive           141                                  56.5 ± 4.2                     52.2 ± 6.0                  50.7 ± 9.5                69.3 ± 3.9   60.3 ± 5.9    55.1 ± 9.2    

  **DNA index**                                                                                                                                                                             

  1.16-1.60              1538                                 83.5 ± 1.0                     80.7 ± 1.5                  79.4 ± 3.5    \< 0.0001   94.7 ± 0.6   92.2 ± 1.0    90.5 ± 2.5    \< 0.0001

  \< 1.16                4383                                 69.5 ± 0.7                     65.7 ± 1.1                  63.9 ± 2.2                83.0 ± 0.6   79.3 ± 0.9    77.3 ± 1.9    

  Other                  41                                   74.2 ± 7.1                     68.7 ± 14.5                                           87.1 ± 5.4   81.7 ± 12.4                 

  **Trisomy 4 & 10**                                                                                                                                                                        

  Present                1100                                 86.2 ± 1.1                     83.1 ± 1.6                  82.4 ± 3.9    \< 0.0001   95.9 ± 0.6   94.0 ± 1.0    91.8 ± 2.7    \< 0.0001

  Absent                 4256                                 70.2 ± 0.7                     66.3 ± 1.1                  64.5 ± 2.2                83.5 ± 0.6   79.9 ± 0.9    78.0 ± 1.9    

  **TEL-AML1**                                                                                                                                                                              

  Present                244                                  86.2 ± 2.3                     80.7 ± 8.6                                \< 0.0001   96.2 ± 1.3   93.8 ± 4.9                  \< 0.0001

  Absent                 682                                  72.1 ± 1.8                     68.8 ± 5.7                                            84.5 ± 1.4   81.0 ± 4.8                  

  **t(9;22)**                                                                                                                                                                               

  Present                128                                  24.9 ± 3.9                     19.4 ± 4.7                  17.0 ± 7.0    \< 0.0001   34.8 ± 4.3   32.7 ± 5.5    31.0 ± 9.7    \< 0.0001

  Absent                 5228                                 74.7 ± 0.6                     71.0 ± 0.9                  69.4 ± 2.0                87.3 ± 0.5   84.0 ± 0.7    82.1 ± 1.6    

  **t(1;19)**                                                                                                                                                                               

  Present                259                                  74.5 ± 2.8                     71.4 ± 4.6                  71.4 ± 12.1   0.891       83.3 ± 2.4   80.9 ± 3.8    80.9 ± 10.2   0.377

  Absent                 5097                                 73.4 ± 0.6                     69.7 ± 0.9                  68.0 ± 2.0                86.2 ± 0.5   82.9 ± 0.8    80.9 ± 1.6    

  **t(4;11)**                                                                                                                                                                               

  Present                67                                   47.8 ± 6.1                     46.2 ± 11.3                 46.2 ± 24.0   \< 0.0001   65.7 ± 5.8   64.1 ± 10.7   64.1 ± 19.2   \< 0.0001

  Absent                 6457                                 73.8 ± 0.6                     70.1 ± 0.8                  68.5 ± 1.7                86.4 ± 0.4   82.9 ± 0.7    81.0 ± 1.4    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The total number of patients is 6524. Of these 58 patients that were on the ALinC17 pilot (run as part of the ALinc16 series) were excluded from the outcome analyses by series (total pts 6466). All 6524 pts are included in the analyses by presenting features. Some presenting features were missing for subsets of patients, and hence totals for each of them do not add up to 6524 pts.

###### 

B-precursor ALL: Randomized Regimen Comparisons

  ------------------------------------------------------------------------------------------------------------------------------------
  Regimen                     No. of\    Event-free survival ± SE (%)                             
                              patients                                                            
  --------------------------- ---------- ------------------------------ ------------ ------------ ------------------------------------
    **8602 (lower risk)**                                                                         

      *Early Pre-B*                                                                               

  A (Upfront IDM)             228        77.8 ± 2.8                     76.3 ± 3.1   74.0 ± 4.4   0.53

  B (Upfront IDM & ASP)       295        79.6 ± 2.4                     74.6 ± 2.8   71.7 ± 4.1   

  A (Upfront IDM)             228        77.8 ± 2.8                     76.3 ± 3.1   74.0 ± 4.4   0.25

  C (Upfront IDM AC)          399        82.1 ± 1.9                     79.2 ± 2.3   78.8 ± 3.2   

  C (Upfront IDM AC)          399        82.1 ± 1.9                     79.2 ± 2.3   78.8 ± 3.2   0.94

  D (IDM AC)                  117        84.4 ± 3.4                     79.8 ± 4.0   78.3 ± 5.7   

      *Pre-B*                                                                                     

  B (Upfront IDM & ASP)       205        65.2 ± 3.4                     63.2 ± 3.6   59.6 ± 5.4   0.0246

  C (Upfront IDM AC)          308        74.0 ± 2.5                     70.3 ± 2.9   69.9 ± 4.2   

    **8602 (higher risk)**                                                                        

  C (Upfront IDM ARAC)        354        64.8 ± 2.6                     58.8 ± 3.0   58.0 ± 4.3   0.79

  D (IDM ARAC)                96         61.3 ± 5.1                     57.9 ± 5.6   57.9 ± 7.8   

    **9005 (lower risk)**                                                                         

  A (ID MTX, ID 6MP)          330        80.2 ± 2.2                     77.5 ± 2.7                0.0014

  B (PO MTX, ID 6MP)          336        71.4 ± 2.6                     66.3 ± 3.1                

  A (ID MTX, ID 6MP)          311        78.3 ± 2.4                     75.6 ± 3.2                0.30

  C (ID MTX)                  307        81.2 ± 2.3                     78.4 ± 3.1                

    **9006 (higher risk)**                                                                        

  A (Intensive)               266        60.4 ± 3.0                     56.5 ± 4.0                0.24

  B (Alternating)             271        63.6 ± 3.0                     60.0 ± 3.7                

    **9201 (lower risk)**                                                                         

  Regimen A                   649        88.0 ± 1.3                     85.7 ± 2.7                

    **9605 (Average Risk)**                                                                       

  IMMTX                       526        76.9 ± 1.9                     72.4 ± 7.8                0.11

  ddMTX                       537        80.2 ± 1.8                     74.5 ± 6.6                

    **9605 (Average Risk)**                                                                       

  6MP                         532        76.8 ± 1.9                     71.5 ± 7.1                0.16

  dd 6MP                      531        80.4 ± 1.8                     76.5 ± 7.1                

    **9605 (Average Risk)**                                                                       

  A (IM MTX/daily MP)         266        71.1 ± 2.8                     67.2 ± 3.1                N/A[1](#TFN9){ref-type="table-fn"}

  B (dd MTX/daily MP)         266        82.4 ± 2.4                     75.9 ± 4.3                

  C (IM MTX/twice daily MP)   260        82.8 ± 2.4                     77.8 ± 3                  

  D (dd MTX/twice daily MP)   271        78 ± 2.6                       75.3 ± 2.8                

    **9406 (Higher Risk)**                                                                        

  IDMTX                       483        66.9 ± 2.2                     61.2 ± 4.9                0.33

  Higher dose IDMTX           424        68.7 ± 2.3                     66.2 ± 5.4                

    **9406 (Higher Risk)**                                                                        

  No HDAC                     391        70.4 ± 2.4                     66.3 ± 5.6                0.41

  HDAC                        395        73 ± 2.3                       67.5 ± 5.7                
  ------------------------------------------------------------------------------------------------------------------------------------

powered to answer a 2×2 factorial design, not powered to answer a 4 arm study

###### 

B-precursor ALL: Response and Event Summary by Era

                                B-lineage by Series                         
  ----------------------------- --------------------- ---------- ---------- ----------
  ***All patients***            1276                  1292       1963       4531
  **First Event**                                                           
  **No Event**                                                              
  **Induction Failure**         33                    26         18         77
  **Induction Death**           22                    13         14         49
  **Relapse**                   545                   522        580        1647
  **Isolated Marrow**           285                   274        297        856
  **Isolated CNS**              80                    89         82         251
  **Other**                     180                   159        201        540
  **Second Malignancy**         15                    15         19         49
  **Remission Death**           42                    28         43         113
  **Response**                  1871                  1845       2601       6317
  **Complete Remission**                                                    
  **Induction Failure/Death**   49                    34         31         114
  **Other**                     13                    17         5          35
  **Total**                     **1933**              **1896**   **2637**   **6466**
  ***NCI Standard Risk***       1003                  992        1376       3371
  **First Event**                                                           
  **No Event**                                                              
  **Induction Failure**         7                     7          4          18
  **Induction Death**           11                    7          5          23
  **Relapse**                   299                   316        325        940
  **Isolated Marrow**           148                   166        156        470
  **Isolated CNS**              43                    49         47         139
  **Other**                     108                   101        122        331
  **Second Malignancy**         10                    9          10         29
  **Remission Death**           27                    12         13         52
  **Response**                  1333                  1320       1722       4375
  **Complete Remission**                                                    
  **Induction Failure/Death**   18                    13         9          40
  **Other**                     6                     10         2          18
  **Total**                     **1357**              **1343**   **1733**   **4433**
  ***NCI High Risk***           273                   300        587        1160
  **First Event**                                                           
  **No Event**                                                              
  **Induction Failure**         26                    19         14         59
  **Induction Death**           11                    6          9          26
  **Relapse**                   246                   206        255        707
  **Isolated Marrow**           137                   108        141        386
  **Isolated CNS**              37                    40         35         112
  **Other**                     72                    58         79         209
  **Second Malignancy**         5                     6          9          20
  **Remission Death**           15                    16         30         61
  **Response**                  538                   525        879        1942
  **Complete Remission**                                                    
  **Induction Failure/Death**   31                    21         22         74
  **Other**                     7                     7          3          17
  **Total**                     **576**               **553**    **904**    **2033**

###### 

B-precursor ALL: Cumulative Incidence Rates

  ---------------------------------------------------------------------------------------------------------
  Patients       Event Type             \# of\     Cumulative Incidence ± SE (%)                
                                        patients                                                
  -------------- ---------------------- ---------- ------------------------------- ------------ -----------
  **Alinc 14**   Any CNS Relapse        1871       7.2 ± 0.6                       7.7 ± 0.6    7.8 ± 0.6

                 Isolated CNS Relapse   1871       4.1 ± 0.5                       4.3 ± 0.5    4.3 ± 0.5

                 Second Malignancy      1871       0.2 ± 0.1                       0.6 ± 0.2    0.8 ± 0.2

                 Remission Death        1871       1.6 ± 0.3                       1.9 ± 0.3    2.3 ± 0.4

  **Alinc 15**   Any CNS Relapse        1845       7.8 ± 0.6                       8.3 ± 0.6    

                 Isolated CNS Relapse   1845       4.6 ± 0.5                       4.8 ± 0.5    

                 Second Malignancy      1845       0.4 ± 0.2                       0.8 ± 0.2    

                 Remission Death        1845       1.3 ± 0.3                       1.4 ± 0.3    

  **Alinc 16**   Any CNS Relapse        2601       5.6 ± 0.5                       6.1 ± 0.5    

                 Isolated CNS Relapse   2601       3.1 ± 0.3                       3.2 ± 0.3    

                 Second Malignancy      2601       0.6 ± 0.2                       0.8 ± 0.2    

                 Remission Death        2601       1.5 ± 0.2                       2.0 ± 0.4    

  **POG 8602**   Any CNS Relapse        1871       7.2 ± 0.6                       7.7 ± 0.6    7.8 ± 0.6

                 Isolated CNS Relapse   1871       4.1 ± 0.5                       4.3 ± 0.5    4.3 ± 0.5

                 Second Malignancy      1871       0.2 ± 0.1                       0.6 ± 0.2    0.8 ± 0.2

                 Remission Death        1871       1.6 ± 0.3                       1.9 ± 0.3    2.3 ± 0.4

  **POG 9005**   Any CNS Relapse        1264       5.8 ± 0.7                       6.5 ± 0.7    

                 Isolated CNS Relapse   1264       3.2 ± 0.5                       3.5 ± 0.5    

                 Second Malignancy      1264       0.4 ± 0.2                       0.7 ± 0.2    

                 Remission Death        1264       0.8 ± 0.3                       0.8 ± 0.3    

  **POG 9006**   Any CNS Relapse        581        12.1 ± 1.4                      12.3 ± 1.4   

                 Isolated CNS Relapse   581        7.6 ± 1.1                       7.6 ± 1.1    

                 Second Malignancy      581        0.5 ± 0.3                       1.2 ± 0.5    

                 Remission Death        581        2.2 ± 0.6                       2.8 ± 0.7    

  **POG 9201**   Any CNS Relapse        650        3.7 ± 0.8                       4.1 ± 0.8    

                 Isolated CNS Relapse   650        2.2 ± 0.6                       2.2 ± 0.6    

                 Second Malignancy      650        0.3 ± 0.2                       0.3 ± 0.2    

                 Remission Death        650        0.3 ± 0.2                       0.3 ± 0.2    

  **POG 9605**   Any CNS Relapse        1068       6.1 ± 0.7                       6.8 ± 0.8    

                 Isolated CNS Relapse   1068       2.9 ± 0.5                       3.2 ± 0.5    

                 Second Malignancy      1068       0.7 ± 0.3                       0.7 ± 0.3    

                 Remission Death        1068       0.7 ± 0.2                       1.0 ± 0.4    

  **POG 9406**   Any CNS Relapse        883        6.5 ± 0.8                       6.9 ± 0.9    

                 Isolated CNS Relapse   883        3.9 ± 0.7                       4.0 ± 0.7    

                 Second Malignancy      883        0.8 ± 0.3                       1.2 ± 0.4    

                 Remission Death        883        3.3 ± 0.6                       4.4 ± 0.9    
  ---------------------------------------------------------------------------------------------------------

###### 

T-cell ALL: Outcomes by Presenting Features

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factors                No. of\    Event-free survival ± SE (%)   Overall survival ± SE (%)                                                                      
                         patients                                                                                                                                 
  ---------------------- ---------- ------------------------------ --------------------------- ------------- ----------- ------------ ------------- ------------- -----------
  **Study**                                                                                                                                                       

  8704                   342        49.7 ± 2.7                     49.1 ± 3.1                  47.5 ± 5.9    \< 0.0001   59.8 ± 2.7   55.3 ± 3.1    54.9 ± 5.0    \< 0.0001

  9404                   363        74.0 ± 2.4                     72.2 ± 4.7                                            80.8 ± 2.2   78.8 ± 4.4                  

  **NCI Risk**                                                                                                                                                    

  Standard               176        71.5 ± 3.5                     69.7 ± 4.8                  69.7 ± 10.6   0.0028      80.0 ± 3.1   75.0 ± 4.5    75.0 ± 10.4   0.0050

  High                   529        59.0 ± 2.2                     58.2 ± 3.3                  54.4 ± 6.0                67.5 ± 2.1   64.6 ± 3.2    64.1 ± 5.9    

  **Gender**                                                                                                                                                      

  Male                   530        58.4 ± 2.2                     57.5 ± 3.3                  53.6 ± 6.5    0.0002      68.4 ± 2.1   64.4 ± 3.1    63.9 ± 6.5    0.0055

  Female                 175        73.6 ± 3.4                     71.8 ± 4.9                  71.8 ± 8.8                77.5 ± 3.2   75.7 ± 4.7    75.7 ± 8.4    

  **Age at diagnosis**                                                                                                                                            

  1-9 yrs                412        64.2 ± 2.4                     63.1 ± 3.3                  59.6 ± 6.2    0.1005      73.8 ± 2.2   70.0 ± 3.1    69.5 ± 6.1    0.0253

  ≥10 yrs                293        59.3 ± 3.0                     58.0 ± 5.2                  56.9 ± 10.0               66.1 ± 2.9   63.4 ± 5.0    63.4 ± 9.9    

  **Race**                                                                                                                                                        

  White                  48         9 62.7 ± 2.2                   62.1 ± 3.1                  58.8 ± 5.7    0.3594      72.0 ± 2.1   68.9 ± 2.9    68.5 ± 5.6    0.2000

  Black                  119        58.7 ± 4.8                     57.5 ± 8.4                  57.5 ± 15.3               63.7 ± 4.7   61.8 ± 8.1    61.8 ± 15.6   

  Hispanic               61         67.2 ± 6.2                     67.2 ± 11.1                 67.2 ± 38.5               73.6 ± 5.9   71.1 ± 10.2   71.1 ± 27.0   

  Other                  36         58.3 ± 8.2                     48.6 ± 20.1                                           69.4 ± 7.7   55.8 ± 15.2                 

  **WBC×10^3^/μl**                                                                                                                                                

  \<50                   299        69.1 ± 2.8                     68.0 ± 4.2                  67.2 ± 9.1    0.0011      76.4 ± 2.5   72.2 ± 4.0    72.2 ± 8.7    0.004

  50-100                 126        61.6 ± 4.5                     61.6 ± 5.9                  53.4 ± 12.2               72.8 ± 4.1   70.2 ± 5.5    70.2 ± 11.6   

  ≥100                   280        54.9 ± 3.0                     53.4 ± 4.5                  51.5 ± 7.3                63.4 ± 3.0   60.4 ± 4.0    59.5 ± 7.6    

  **CNS status**                                                                                                                                                  

  CNS negative           639        61.8 ± 2.0                     60.6 ± 2.9                  58.2 ± 5.7    0.5555      70.9 ± 1.9   67.2 ± 2.8    66.8 ± 5.6    0.8611

  CNS positive           66         65.2 ± 5.9                     65.2 ± 8.0                  60.1 ± 13.4               68.2 ± 5.8   66.6 ± 8.0    66.6 ± 13.6   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

T-Cell ALL: Randomized Regimen Comparisons

  Regimen                  No. of patients   Event-free survival ± SE (%)                             
  ------------------------ ----------------- ------------------------------ ------------ ------------ --------
  **8704**                                                                                            
  No Asp                   157               42.7 ± 4.0                     42.7 ± 4.6   40.7 ± 7.4   0.0012
  Asp                      160               63.1 ± 3.8                     61.8 ± 4.3   60.2 ± 6.6   
  **9404 (HDMTX)**                                                                                    
  No HDMTX                 151               67.5 ± 3.9                     65.8 ± 7.3                0.029
  HDMTX                    148               80.2 ± 3.4                     78.0 ± 6.0                
  **9404 (Dexrazoxane)**                                                                              
  No Dexrazoxane           176               74.4 ± 3.4                     73.0 ± 6.4                0.85
  Dexrazoxane              187               73.6 ± 3.4                     71.3 ± 7.0                

###### 

T-Cell ALL: Response and Event Summary by Study

                                T-Cell by Study   Total     
  ----------------------------- ----------------- --------- ---------
  **First Event**               165               262       428
  **No Event**                                              
  **Induction Failure**         5                 27        32
  **Induction Death**           9                 3         12
  **Relapse**                   138               57        195
  **Isolated Marrow**           72                13        85
  **Isolated CNS**              11                23        34
  **Other**                     55                21        76
  **Second Malignancy**         14                8         22
  **Remission Death**           11                6         17
  **Response**                  326               332       658
  **Complete Remission**                                    
  **Induction Failure/Death**   14                30        44
  **Other**                     2                 1         3
  **Total**                     **342**           **363**   **705**

###### 

T-Cell ALL: Cumulative Incidence Rates

  -------------------------------------------------------------------------------------------------------------------------
  Study                    Event Type             \# of\     Cumulative Incidence ± SE (%)   P-value                 
                                                  patients                                                           
  ------------------------ ---------------------- ---------- ------------------------------- ----------- ----------- ------
  **8704**                 Any CNS Relapse        326        8.9 ± 1.6                       9.8 ± 1.7   9.8 ± 1.7   

                           Isolated CNS Relapse   326        3.4 ± 1.0                       3.4 ± 1.0   3.4 ± 1.0   

                           Second Malignancy      326        3.4 ± 1.0                       4 ± 1.1     4.9 ± 1.4   

                           Remission Death        326        2.8 ± 0.9                       3.1 ± 1.0   3.5 ± 1.0   

  **9404**                 Any CNS Relapse        332        9.4 ± 1.6                       9.4 ± 1.6               

                           Isolated CNS Relapse   332        7.0 ± 1.4                       7.0 ± 1.4               

                           Second Malignancy      332        1.8 ± 0.7                       2.8 ± 1.2               

                           Remission Death        332        1.9 ± 0.8                       1.9 ± 0.8               

  **8704**                                                                                                           

  No ASP                   Second Malignancy      156        1.9 ± 1.1                       1.9 ± 1.1   3.9 ± 2.2   0.11

  ASP                                             159        5.7 ± 1.8                       6.3 ± 1.9   6.3 ± 1.9   

  **9404 (HDMTX)**                                                                                                   

  No HDMTX                 Second Malignancy      136        2.2 ± 1.3                       4.1 ± 2.3               0.81

  HDMTX                                           138        2.3 ± 1.3                       2.3 ± 1.3               

  **9404 (Dexrazoxane)**                                                                                             

  No Dexrazoxane           Second Malignancy      159        1.3± 0.9                        1.3 ± 0.9               0.15

  Dexrazoxane                                     173        2.3 ± 1.2                       4.2 ± 2.2               
  -------------------------------------------------------------------------------------------------------------------------

###### 

Infant ALL: Outcomes by Presenting Features

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factors            No. of\    Event-free survival ± SE (%)   Overall survival ± SE (%)                                                                      
                     patients                                                                                                                                 
  ------------------ ---------- ------------------------------ --------------------------- ------------- ---------- ------------- ------------- ------------- -----------
  **Study**                                                                                                                                                   

  8398               33         17.7 ± 7.2                     17.7 ± 7.2                                0.658      36.4 ± 8.8    36.4 ± 9.2    36.4 ± 16.8   0.558

  8493               84         25.0 ± 4.8                     22.4 ± 5.5                  22.4 ± 7.4               31.6 ± 5.2    30.3 ± 6.0    28 ± 7.9      

  9107               47         31.9 ± 7.0                     31.9 ± 8.3                                           40.2 ± 7.3    38.0 ± 9.0                  

  **Cell lineage**                                                                                                                                            

  B                  159        25.7 ± 3.6                     24.3 ± 4.1                  23.3 ± 7.7    0.657      35.5 ± 3.9    34.2 ± 4.5    32.7 ± 7.8    0.434

  T                  5          20.0 ± 17.9                    20.0 ± 17.9                                          20.0 ± 17.9   20.0 ± 17.9                 

  **Gender**                                                                                                                                                  

  Male               79         26.5 ± 5.1                     25.2 ± 5.8                  25.2 ± 12.6   0.263      40.5 ± 5.6    37.9 ± 6.2    37.9 ± 10.6   0.151

  Female             85         24.7 ± 4.9                     23.2 ± 5.4                  21.3 ± 9.4               30.0 ± 5.2    30.0 ± 6.3    26.2 ± 11.3   

  **Race**                                                                                                                                                    

  White              117        26.4 ± 4.3                     24.4 ± 4.7                  22.9 ± 9.0    0.532      34.0 ± 4.5    32.1 ± 5.0    30.3 ± 8.4    0.857

  Black              20         30.0 ± 10.3                    30.0 ± 10.3                 30.0 ± 10.3              35.0 ± 10.7   35.0 ± 10.7   35.0 ± 20.0   

  Hispanic           20         25.0 ± 9.7                     25.0 ± 15.3                 25.0 ± 22.0              40.0 ± 11.0   40.0 ± 21.9   40.0 ± 31.0   

  Other              7          0 ±[0]{.ul}                                                                         42.9 ± 22.9   42.9 ± 22.9                 

  **WBC×10^3^/μl**                                                                                                                                            

  \<50               61         47.3 ± 6.7                     43.4 ± 7.9                  40.7 ± 15.7   \<0.0001   60.5 ± 6.5    56.9 ± 7.6    53.1 ± 12.9   \< 0.0001

  50-100             29         13.8 ± 6.4                     13.8 ± 6.4                  13.8 ± 12.8              20.7 ± 7.5    20.7 ± 9.2    20.7 ± 18.4   

  ≥100               73         12.3 ± 3.9                     12.3 ± 4.4                  12.3 ± 8.2               19.8 ± 4.8    19.8 ± 5.4    19.8 ± 10.3   

  **CNS status**                                                                                                                                              

  CNS negative       112        27.6 ± 4.4                     25.6 ± 4.9                  24.1 ± 8.6    0.855      38.9 ± 4.8    37.0 ± 5.5    34.8 ± 8.9    0.409

  CNS positive       37         27.0 ± 7.7                     27.0 ± 8.7                  27.0 ± 23.1              29.7 ± 7.9    29.7 ± 9.4    29.7 ± 24.9   

  **t(4;11)**                                                                                                                                                 

  Present            52         15.4 ± 5.4                     15.4 ± 5.8                  15.4 ± 14.2   0.017      25.0 ± 6.3    22.9 ± 7.1    22.9 ± 14.2   0.024

  Absent             112        30.2 ± 4.5                     28.2 ± 5.1                  26.8 ± 9.4               39.7 ± 4.8    38.8 ± 5.5    36.8 ± 9.3    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Infant ALL: Response and Event Summary by Study

                                Infants by Study   Total             
  ----------------------------- ------------------ -------- -------- ---------
  **First Event**               6                  19       14       39
  **No Event**                                                       
  **Induction Failure**         2                  2        1        5
  **Induction Death**           0                  6        3        9
  **Relapse**                   23                 51       24       98
  **Isolated Marrow**           13                 35       17       65
  **Isolated CNS**              0                  3        2        5
  **Other**                     10                 13       5        28
  **Second Malignancy**         0                  0        1        1
  **Remission Death**           2                  6        4        12
  **Response**                  31                 75       42       148
  **Complete Remission**                                             
  **Induction Failure/Death**   2                  7        4        13
  **Other**                     0                  2        1        3
  **Total**                     **33**             **84**   **47**   **164**

###### 

Infant ALL: Cumulative Incidence Rates

  ---------------------------------------------------------------------------------------------------------
  Study         Event Type             \# of\     Cumulative Incidence ± SE (%)                
                                       patients                                                
  ------------- ---------------------- ---------- ------------------------------- ------------ ------------
  **Overall**   Any CNS Relapse        148        14.3 ± 2.9                      14.3 ± 2.9   14.3 ± 2.9

                Isolated CNS Relapse   148        3.4 ± 1.5                       3.4 ± 1.5    3.4 ± 1.5

                Second Malignancy      148        0 ± 0                           0 ± 0        1.1 ± 1.1

                Remission Death        148        7.4 ± 2.2                       8.2 ± 2.3    8.2 ± 2.3

  **8398**      Any CNS Relapse        31         16.7 ± 7.2                                   

                Isolated CNS Relapse   31         0 ± 0                                        

                Second Malignancy      31         0 ± 0                                        

                Death                  31         6.5 ± 4.6                                    

  **8493**      Any CNS Relapse        75         14.7 ± 4.1                      14.7 ± 4.1   14.7 ± 4.1

                Isolated CNS Relapse   75         4.0 ± 2.3                       4.0 ± 2.3    4.0 ± 2.3

                Second Malignancy      75         0 ± 0                           0 ± 0        0 ± 0

                Death                  75         6.7 ± 2.9                       8.1 ± 3.2    8.1 ± 3.2

  **9107**      Any CNS Relapse        42         11.9 ± 5.1                      11.9 ± 5.1   

                Isolated CNS Relapse   42         4.8 ± 3.3                       4.8 ± 3.3    

                Second Malignancy      42         0 ± 0                           3.3 ± 3.4    

                Death                  42         9.5 ± 4.6                       9.5 ± 4.6    
  ---------------------------------------------------------------------------------------------------------

###### 

Multivariate Analyses

  --------------------------------------------------------------------------------------------
  Patients                          N         Factor                       p-value   Hazard\
                                                                                     Ratio
  --------------------------------- --------- ---------------------------- --------- ---------
  **Infant ALL**                    148       LINEAGE: T vs. B             0.2284    2.162

  GENDER: M vs. F                   0.4931    0.868                                  

  RACE: Black vs. White             0.3654    0.759                                  

  RACE: Hispanic vs. White          0.9852    1.006                                  

  RACE: Other vs. White             0.6489    1.229                                  

  WBC: 50-100 vs. \<50              0.0093    2.132                                  

  WBC: ≥100 vs. \<50                0.0003    2.448                                  

  CNS status: Pos vs. Neg           0.8113    1.062                                  

  MLL: Present vs. Absent           0.0564    1.527                                  

  **Non-Infant B-precursor ALL**    4959      NCI Standard vs. High risk   0.7534    0.960

  GENDER: M vs. F                   \<.0001   1.498                                  

  AGE: \>10 vs. 1-9                 \<.0001   1.644                                  

  RACE: Black vs. White             0.0026    1.287                                  

  RACE: Hispanic vs. White          \<.0001   1.386                                  

  RACE: Other vs. White             0.9544    0.993                                  

  WBC: 10-50 vs. \<10               \<.0001   1.425                                  

  WBC: 50-100 vs. \<10              \<.0001   1.630                                  

  WBC: ≥100 vs. \<10                \<.0001   2.456                                  

  CNS status: Pos vs. Neg           0.0382    1.342                                  

  DI: \<=1.16 vs. 1.16-1.60         0.0002    1.415                                  

  DI: Other vs. 1.16-1.60           0.3406    1.413                                  

  t(9;22): Present vs. Absent       \<.0001   3.734                                  

  t(1;19): Present vs. Absent       0.0079    0.710                                  

  t(4;11): Present vs. Absent       0.0884    1.367                                  

  TRISOMY4/10: Present vs. Absent   0.0049    0.740                                  

  **Non-Infant T-cell ALL**         705       NCI Standard vs. NCI High    0.6604    0.894

  GENDER: M vs. F                   0.0005    1.744                                  

  AGE: \>10 vs. 1-9                 0.1782    1.226                                  

  RACE: Black vs. White             0.1472    1.264                                  

  RACE: Hispanic vs. White          0.8702    0.962                                  

  RACE: Other vs. White             0.2570    1.327                                  

  WBC: 50-100 vs. \<50              0.5622    1.141                                  

  WBC: ≥100 vs. \<50                0.0649    1.437                                  

  CNS status: Pos vs. Neg           0.3244    0.809                                  
  --------------------------------------------------------------------------------------------
